Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Ovid Therapeutics Inc. has a significant holder reporting updated passive ownership. ADAR1 Capital Management, LLC and its manager Daniel Schneeberger report beneficial ownership of 9,559,979 shares of Ovid common stock, representing 5.1% of the class, all with shared voting and dispositive power. This stake includes 6,980,088 common shares held by ADAR1 Partners, LP, 435,032 shares held by Spearhead Insurance Solutions IDF, LLC, 2,359 shares held in separately managed accounts and 2,142,500 shares underlying warrants held by ADAR1 Partners, LP that are subject to 9.99% beneficial ownership limitations.
ADAR1 Capital Management GP, LLC, as general partner of ADAR1 Partners, LP, reports beneficial ownership of 9,122,588 shares, or 4.9% of the class, and characterizes this amendment as an exit filing solely for ADAR1 General Partner after falling below the 5% threshold. Ownership is calculated based on 184,755,735 Ovid common shares outstanding as of June 30, 2026.
Key Figures
Beneficial ownership (ADAR1 Capital Management & Schneeberger):9,559,979 shares (5.1%)Beneficial ownership (ADAR1 Capital Management GP):9,122,588 shares (4.9%)Shares outstanding:184,755,735 shares+4 more
7 metrics
Beneficial ownership (ADAR1 Capital Management & Schneeberger)9,559,979 shares (5.1%)Ovid common stock beneficially owned with shared voting and dispositive power
Beneficial ownership (ADAR1 Capital Management GP)9,122,588 shares (4.9%)Ovid common stock beneficially owned by the general partner, exit filing below 5%
Shares outstanding184,755,735 sharesOvid common stock outstanding as of June 30, 2026
Common shares held by ADAR1 Partners, LP6,980,088 sharesHeld directly by ADAR1 Partners, LP
Common shares held by Spearhead Insurance Solutions IDF, LLC435,032 sharesIncluded in ADAR1 Capital Management and Schneeberger beneficial ownership
Common shares in separately managed accounts2,359 sharesOther accounts managed by ADAR1 Capital Management
Warrant shares subject to 9.99% limit2,142,500 sharesCommon stock underlying warrants held by ADAR1 Partners, LP
"ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting powerfinancial
"Shared Voting Power 9,559,979.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 9,559,979.00"
beneficial ownership limitationsfinancial
"shares of Common Stock underlying warrants...subject to 9.99% beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
control personfinancial
"Mr. Schneeberger is filing this as a control person in respect of shares"
A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Ovid Therapeutics (OVID) does ADAR1 Capital Management report?
ADAR1 Capital Management and Daniel Schneeberger report beneficial ownership of 9,559,979 shares of Ovid Therapeutics common stock, representing 5.1% of the outstanding class, with shared voting and dispositive power across affiliated entities and accounts.
Why is this Schedule 13G/A an exit filing for ADAR1 Capital Management GP in OVID?
ADAR1 Capital Management GP, LLC reports beneficial ownership of 9,122,588 shares, or 4.9% of Ovid’s common stock. Because this is below the 5% reporting threshold, the amendment is characterized as an exit filing solely for ADAR1 General Partner.
How is ADAR1’s Ovid Therapeutics (OVID) position composed across entities?
The reported 9,559,979 shares include 6,980,088 shares held by ADAR1 Partners, LP, 435,032 by Spearhead Insurance Solutions IDF, LLC, 2,359 by separately managed accounts, plus 2,142,500 shares underlying warrants held by ADAR1 Partners, LP.
What is the warrant-related beneficial ownership limit disclosed for OVID?
The filing states that 2,142,500 Ovid shares underlying warrants held by ADAR1 Partners, LP are subject to 9.99% beneficial ownership limitations, constraining exchanges and exercises that would push the holder’s beneficial ownership above that level.
What share count does Ovid Therapeutics (OVID) use to calculate these ownership percentages?
Ownership percentages are based on 184,755,735 shares of Ovid Therapeutics common stock outstanding as of June 30, 2026, as reported in the company’s Quarterly Report on Form 10-Q filed on August 13, 2026.
Who is Daniel Schneeberger in relation to the Ovid Therapeutics (OVID) holdings?
Daniel Schneeberger, a citizen of Switzerland, is manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC. He may be deemed to indirectly beneficially own the 9,559,979 Ovid shares held through ADAR1-related entities and accounts.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Ovid Therapeutics Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
690469101
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
ADAR1 Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,559,979.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,559,979.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,559,979.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: Includes (i) 6,980,088 shares of common stock, par value $0.001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 435,032 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC, (iii) 2,359 shares of Common Stock held by other separately managed accounts and (iv) 2,142,500 shares of Common Stock underlying warrants held by ADAR1 Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP, as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and as the manager of the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts.
Based on 184,755,735 shares of Common Stock of Ovid Therapeutics Inc (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
ADAR1 Capital Management GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,122,588.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,122,588.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,122,588.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Includes (i) 6,980,088 shares of Common Stock held by ADAR1 Partners, LP and (ii) 2,142,500 shares of Common Stock underlying warrants held by ADAR1 Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
Based on 184,755,735 shares of Common Stock of the Issuer outstanding as of June 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Daniel Schneeberger
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,559,979.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,559,979.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,559,979.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Includes (i) 6,980,088 shares of Common Stock held by ADAR1 Partners, LP, (ii) 435,032 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC, (iii) 2,359 shares of Common Stock held by other separately managed accounts and (iv) 2,142,500 shares of Common Stock underlying warrants held by ADAR1 Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above.
Based on 184,755,735 shares of Common Stock of the Issuer outstanding as of June 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Ovid Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
441 Ninth Avenue, 14th Floor, New York, NY 10001
Item 2.
(a)
Name of person filing:
This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"):
(i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management");
(ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and
(iii) Daniel Schneeberger ("Mr. Schneeberger").
Pursuant to Item 5 below, this filing is an exit filing solely for ADAR1 General Partner.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)
Citizenship:
(i) ADAR1 Capital Management is a Texas limited liability company;
(ii) ADAR1 General Partner is a Texas limited liability company; and
(iii) Mr. Schneeberger is a citizen of Switzerland.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
690469101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)
Percent of class:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
